GeNeuro SA (GNRO.PA)
EUR 0.08
(6.38%)
EUR 0.08
(6.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -14.75 Million EUR | -20.96% |
| 2022 | -12.19 Million EUR | -78.94% |
| 2021 | -6.81 Million EUR | 23.93% |
| 2020 | -8.96 Million EUR | 5.27% |
| 2019 | -9.46 Million EUR | -113505.03% |
| 2018 | -8327.80 EUR | -42.67% |
| 2017 | -5837.20 EUR | 58.61% |
| 2016 | -14.1 Thousand EUR | -214.3% |
| 2015 | -4487.20 EUR | -100.25% |
| 2014 | 1.77 Million EUR | 150.77% |
| 2013 | -3.49 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q4 | -7894.90 EUR | 0.0% |
| 2023 FY | -14.75 Million EUR | -20.96% |
| 2023 Q2 | -6.86 Million EUR | 0.0% |
| 2022 Q4 | -6.52 Million EUR | 0.0% |
| 2022 FY | -12.19 Million EUR | -78.94% |
| 2022 Q2 | -5.67 Million EUR | 0.0% |
| 2021 Q4 | -3.41 Million EUR | 0.0% |
| 2021 Q2 | -3.4 Million EUR | 0.0% |
| 2021 FY | -6.81 Million EUR | 23.93% |
| 2020 FY | -8.96 Million EUR | 5.27% |
| 2020 Q4 | -5.01 Million EUR | 0.0% |
| 2020 Q2 | -3.94 Million EUR | 0.0% |
| 2019 FY | -9.46 Million EUR | -113505.03% |
| 2019 Q4 | -4.99 Million EUR | 0.0% |
| 2019 Q2 | -4.46 Million EUR | 0.0% |
| 2018 Q4 | -5990.80 EUR | 0.0% |
| 2018 Q2 | -2337.00 EUR | 0.0% |
| 2018 FY | -8327.80 EUR | -42.67% |
| 2017 Q4 | 2144.80 EUR | 0.0% |
| 2017 Q2 | -7982.00 EUR | 0.0% |
| 2017 FY | -5837.20 EUR | 58.61% |
| 2016 Q4 | -8195.60 EUR | 0.0% |
| 2016 FY | -14.1 Thousand EUR | -214.3% |
| 2016 Q2 | -5907.70 EUR | 0.0% |
| 2015 Q2 | -1687.40 EUR | 0.0% |
| 2015 FY | -4487.20 EUR | -100.25% |
| 2015 Q4 | -2799.80 EUR | 0.0% |
| 2014 Q3 | 444.1 Thousand EUR | 23838.51% |
| 2014 Q1 | 444.1 Thousand EUR | 0.0% |
| 2014 Q2 | -1870.80 EUR | -100.42% |
| 2014 FY | 1.77 Million EUR | 150.77% |
| 2014 Q4 | 3647.20 EUR | -99.18% |
| 2013 FY | -3.49 Million EUR | 0.0% |
| 2013 Q1 | -874.7 Thousand EUR | 0.0% |
| 2013 Q3 | -874.7 Thousand EUR | 0.0% |
| 2013 Q4 | 444.1 Thousand EUR | 150.77% |
| 2013 Q2 | -874.7 Thousand EUR | 0.0% |
| 2012 Q4 | -874.7 Thousand EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -319.471% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 90.012% |
| Adocia SA | -21.16 Million EUR | 30.267% |
| Aelis Farma SA | -5.07 Million EUR | -190.607% |
| Biophytis S.A. | -17.02 Million EUR | 13.327% |
| Advicenne S.A. | -7.03 Million EUR | -109.885% |
| genOway Société anonyme | 1.56 Million EUR | 1041.39% |
| IntegraGen SA | -171.39 Thousand EUR | -8509.735% |
| Medesis Pharma S.A. | -3.95 Million EUR | -272.699% |
| Neovacs S.A. | -8.74 Million EUR | -68.778% |
| NFL Biosciences SA | -3.74 Million EUR | -293.995% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 18739.872% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -365.381% |
| Sensorion SA | -22.06 Million EUR | 33.115% |
| Theranexus Société Anonyme | -6.82 Million EUR | -116.126% |
| TME Pharma N.V. | -6.73 Million EUR | -119.077% |
| Valbiotis SA | -7.36 Million EUR | -100.285% |
| TheraVet SA | -1.57 Million EUR | -839.513% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | 27.463% |
| argenx SE | -272.91 Million EUR | 94.593% |
| BioSenic S.A. | -28.77 Million EUR | 48.721% |
| Celyad Oncology SA | -8.44 Million EUR | -74.68% |
| DBV Technologies S.A. | -67.26 Million EUR | 78.063% |
| Galapagos NV | 211.69 Million EUR | 106.971% |
| Genfit S.A. | -28.89 Million EUR | 48.927% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | 4.051% |
| Innate Pharma S.A. | -7.57 Million EUR | -94.941% |
| Inventiva S.A. | -110.42 Million EUR | 86.636% |
| MaaT Pharma SA | -19.71 Million EUR | 25.156% |
| MedinCell S.A. | -25.03 Million EUR | 41.062% |
| Nanobiotix S.A. | -39.7 Million EUR | 62.829% |
| Onward Medical N.V. | -36.18 Million EUR | 59.213% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -340.121% |
| OSE Immunotherapeutics SA | -23 Million EUR | 35.847% |
| Oxurion NV | -18.96 Million EUR | 22.205% |
| Pharming Group N.V. | -9.75 Million EUR | -51.252% |
| Poxel S.A. | -35.09 Million EUR | 57.945% |
| GenSight Biologics S.A. | -26.22 Million EUR | 43.719% |
| Transgene SA | -22.32 Million EUR | 33.908% |
| Financière de Tubize SA | 88.15 Million EUR | 116.741% |
| UCB SA | 343 Million EUR | 104.302% |
| Valneva SE | -101.42 Million EUR | 85.451% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 47.932% |